Chimerix Inc (CMRX):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Chimerix Inc (CMRX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C7977
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:40
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Chimerix Inc (Chimerix) is a biopharmaceutical company that develops, discovers, and commercializes novel and oral antiviral therapeutics. The company’s brincidofovir is an oral nucleotide analog to treat dsDNA viruses, adenovirus, cytomegalovirus, BK virus and herpes simplex viruses. It also develops active compounds against malaria, influenza A and B, brincidofovir for smallpox, dengue virus and tuberculosis, brincidofovir and adenovirus, among others. Chimerix’s lipid antiviral conjugate technology is used to modify a drug molecule order that it mimics a naturally occurring phospholipid metabolite. The company provides research and development services in the areas of CMV and BK virus, influenza, norovirus, and viruses that have significant global impact and there are currently no effective treatments, antivirals are associated with known toxicities such as bone marrow suppression and renal impairment. Chimerix is headquartered in Durham, North Carolina, the US.

Chimerix Inc (CMRX) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Chimerix Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Chimerix Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Chimerix Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Chimerix Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Chimerix Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Chimerix Inc, Pharmaceuticals & Healthcare, Deal Details 10
Licensing Agreements 10
Chimerix Enters into Licensing Agreement with ContraVir Pharma for CMX157 10
Equity Offering 12
Chimerix to Raise USD75 Million in Public Offering of Shares 12
Chimerix Completes Exercise of Over-Allotment Option for Public Offering of Shares for USD22.5 Million 13
Chimerix Raises USD122 Million in Public Offering of Shares 15
Chimerix Raises USD119.4 Million in Public Offering of Shares 17
Chimerix Completes IPO For US$118 Million 19
Chimerix Inc – Key Competitors 21
Chimerix Inc – Key Employees 22
Chimerix Inc – Locations And Subsidiaries 23
Head Office 23
Other Locations & Subsidiaries 23
Recent Developments 24
Financial Announcements 24
Aug 08, 2018: Chimerix announces second quarter 2018 financial results 24
May 07, 2018: Chimerix Reports First Quarter 2018 Financial Results 26
Mar 01, 2018: Chimerix Announces Fourth Quarter and Full Year 2017 Financial Results 28
Nov 08, 2017: Chimerix Announces Third Quarter 2017 Financial Results 30
Aug 07, 2017: Chimerix Announces Second Quarter 2017 Financial Results 32
May 09, 2017: Chimerix Announces First Quarter 2017 Financial Results 33
Mar 02, 2017: Chimerix Announces Fourth Quarter and Full Year 2016 Financial Results 35
Corporate Communications 37
Mar 29, 2018: Chimerix Announces Martha J. Demski as Board Chair; Appoints New Members to Board of Directors 37
Product News 38
02/22/2017: Chimerix Announces Final Data from AdVise Trial of Brincidofovir at BMT Tandem Meetings 38
Clinical Trials 39
Jan 06, 2017: Chimerix Announces Preliminary Data from Ongoing Phase 1 Dose Escalation Study of Intravenous Brincidofovir in Healthy Subjects 39
Appendix 40
Methodology 40
About GlobalData 40
Contact Us 40
Disclaimer 40

List of Tables
Chimerix Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Chimerix Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Chimerix Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Chimerix Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Chimerix Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Chimerix Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Chimerix Enters into Licensing Agreement with ContraVir Pharma for CMX157 10
Chimerix to Raise USD75 Million in Public Offering of Shares 12
Chimerix Completes Exercise of Over-Allotment Option for Public Offering of Shares for USD22.5 Million 13
Chimerix Raises USD122 Million in Public Offering of Shares 15
Chimerix Raises USD119.4 Million in Public Offering of Shares 17
Chimerix Completes IPO For US$118 Million 19
Chimerix Inc, Key Competitors 21
Chimerix Inc, Key Employees 22
Chimerix Inc, Subsidiaries 23

List of Figures
Chimerix Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Chimerix Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Chimerix Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Chimerix Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Chimerix Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Chimerix Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Chimerix Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Chimerix Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Chimerix Inc (CMRX):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • The Hershey Co:企業の戦略・SWOT・財務情報
    The Hershey Co - Strategy, SWOT and Corporate Finance Report Summary The Hershey Co - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • Twenty-First Century Fox Inc. (FOXA):企業の財務・戦略的SWOT分析
    Twenty-First Century Fox Inc. (FOXA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • ConforMIS Inc (CFMS):企業の財務・戦略的SWOT分析
    Summary ConforMIS Inc (ConforMIS) is a medical technology company that manufactures, develops, and markets joint replacement implants. The company’s knee replacement implant products include iTotal CR a cruciate-retaining product, iTotal PS a posterior cruciate ligament substituting product, and iDu …
  • Parkland Fuel Corp (PKI):石油・ガス:M&Aディール及び事業提携情報
    Summary Parkland Fuel Corp (Parkland) is a downstream energy company. It markets various fuel and petroleum products, including gasoline, propane, lubricants, diesel, heating oil, and other petroleum products. The company maintains a portfolio of supply relationships, storage infrastructure, and thi …
  • Absa Bank Ltd
    Absa Bank Ltd - Strategy, SWOT and Corporate Finance Report Summary Absa Bank Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Flotek Industries Inc (FTK):企業の財務・戦略的SWOT分析
    Summary Flotek Industries Inc (Flotek) is a developer of chemistry based technology solutions for energy, industrial and consumer applications. The company offers stimulation chemistry, cementing chemistry, improved oil recovery chemistry, drilling fluid additives, and coil tubing chemistry. Its sti …
  • Euromoney Institutional Investor PLC (ERM):企業の財務・戦略的SWOT分析
    Euromoney Institutional Investor PLC (ERM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengt …
  • LifeScan Inc:企業の戦略的SWOT分析
    LifeScan Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Kansas City Power & Light Co:電力:M&Aディール及び事業提携情報
    Summary Kansas City Power & Light Co. (KCP&L), a subsidiary of Great Plains Energy, Inc., is an integrated energy utility that generates, transmits, distributes, and sells electricity. The company generates electricity from nuclear, solar, biogas, wind, hydro, coal, and natural gas sources. Through …
  • Barclaycard:企業の戦略・SWOT・財務情報
    Barclaycard - Strategy, SWOT and Corporate Finance Report Summary Barclaycard - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • Air China Limited:戦略・SWOT・企業財務分析
    Air China Limited - Strategy, SWOT and Corporate Finance Report Summary Air China Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Abide Therapeutics Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Abide Therapeutics Inc (Abide) is a clinical development stage company that discovers and develops therapeutic potential of serine hydrolases to transform the lives of patients with serious unmet medical needs. The company’s pipeline include ABX-1431, a first-in-class inhibitor of the serine …
  • ViraTherapeutics GmbH:製薬・医療:M&Aディール及び事業提携情報
    Summary ViraTherapeutics GmbH (ViraTherapeutics) is a biotechnology company that develops high potential anti-cancer therapeutics based on cancer-destroying oncolytic viruses. The company provides VSV-GP which is a proprietary oncolytic virus platform, which helps in destroying cancer cells and is u …
  • Shangri-La Hotels (Malaysia) Berhad:戦略・SWOT・企業財務分析
    Shangri-La Hotels (Malaysia) Berhad - Strategy, SWOT and Corporate Finance Report Summary Shangri-La Hotels (Malaysia) Berhad - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, …
  • Boston Children’s Hospital-医療機器分野:企業M&A・提携分析
    Summary Boston Children's Hospital (Boston Children’s) is the pediatric medical center that provides a comprehensive range of health care services for children from birth through 21 years of age. Boston Children’s is the primary pediatric teaching affiliate of Harvard Medical School. The organizatio …
  • Spicers Ltd:企業の戦略的SWOT分析
    Spicers Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • LifeAssays AB (LIFE B):医療機器:M&Aディール及び事業提携情報
    Summary LifeAssays AB (LifeAssays) is a medical device company that develops, manufactures and markets in-vitro diagnostic and veterinary care products. The company offers point-of-care diagnostic testing systems. It provides product portfolio such as lifeassays human system and lifeassays veterinar …
  • Ultrapar Participacoes S.A.:企業の戦略・SWOT・財務情報
    Ultrapar Participacoes S.A. - Strategy, SWOT and Corporate Finance Report Summary Ultrapar Participacoes S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • CSB Bancorp Inc (CSBB):企業の財務・戦略的SWOT分析
    CSB Bancorp Inc (CSBB) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • ReCor Medical Inc-医療機器分野:企業M&A・提携分析
    Summary ReCor Medical Inc (ReCor Medical) is a medical device company that designs and manufactures a proprietary ultrasound ablation system for performing renal denervation. The company provides technology such as Percutaneous Renal Denervation System (Paradise), a therapeutic non-focused ultrasoun …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆